Futility Study of Deferoxamine in Intracerebral Hemorrhage
The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain hemorrhage.
Stanford is now accepting new patients for this trial.
- drug : Normal saline
- drug : Deferoxamine
Phase: Phase 2
Ages Eligible For Study:
1. Age ? 18 and ? 80 years 2. The diagnosis of ICH is confirmed by brain CT scan 3. NIHSS score ? 6 and GCS > 6 upon presentation 4. The first dose of the study drug can be administered within 24h of ICH symptom onset 5. Functional independence prior to ICH, defined as pre-ICH mRS ? 1 6. Signed and dated informed consent is obtained.